株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の臍帯血バンク産業 2018年

Global Cord Blood Banking Industry Report 2018

発行 BIOINFORMANT WORLDWIDE, LLC 商品コード 247398
出版日 ページ情報 英文 265 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.58円で換算しております。
Back to Top
世界の臍帯血バンク産業 2018年 Global Cord Blood Banking Industry Report 2018
出版日: 2018年04月30日 ページ情報: 英文 265 Pages
概要

当レポートでは、世界の臍帯血バンク産業の現状と見通しについて調査し、臍帯血バンクの発展の経緯、現在および将来の臍帯血移植で治療可能な疾患、臍帯血バンクのタイプ、関連制度・法規制・認可・要件、臍帯血バンクの収益成長予測、産業に変化をもたらす主な出来事、地域別の動向、主要バンクや業界のインフルエンサーに関する分析などをまとめています。

第1章 要約

第2章 主な出来事のタイムライン

第3章 臍帯血の技術・医学的特徴の概要

  • 臍帯血および臍帯組織:イントロダクション
  • 定義・命名法
  • 臍帯血の技術的利点
  • 幹細胞移植を必要とする可能性
  • 臍帯血・骨髄・末梢血幹細胞移植の比較
  • 臍帯血移植で治療できる症状

第4章 臍帯血市場の概要

  • 幹細胞保存サービスの提供
  • 官 vs. 民の臍帯血保存

第5章 臍帯組織市場の概要

  • 臍帯組織保存の歴史
  • 臍帯血・臍帯組織保存の比較
  • 間充織幹細胞から生成された臍帯組織を調査する臨床試験
  • 米国における臍帯組織の市場浸透
  • 世界における臍帯組織の市場浸透
  • 臍帯組織保存の料金 (世界の分析)

第6章 間充織幹細胞のメリット

  • MSCの発見における重要な日付
  • MSCの物理的評価
  • その他の幹細胞に関連したMSCのメリット

第7章 臍帯血産業における認証評価

第8章 臍帯血市場における主な処理技術

第9章 戦略的共同開発:臍帯血市場における主な提携

  • Cord Blood RegistryとWomen's Health Alliance
  • ViaCordとDestination Maternity (世界最大規模のマタニティウェア小売業者)
  • Precious Cells MiracleとCroydon Health Services NHS Trust
  • CarePilotと"Cord for Life" (Lifeforce Cryobankの臍帯血保存プログラム)
  • Cesca TherapeuticsとUpState Cord Blood Bank
  • New York Blood Center と Pluristem Therapeutics は臍帯血移植の補助治療で協力

第10章 臍帯血バンキングと出生前/新生児/母親への健康サービスの組み合わせ

第11章 臍帯血産業の統合

第12章 臍帯血幹細胞拡張の技術

第13章 幹細胞保存サービスの多様化

  • 歯科幹細胞の保存
  • 脂肪由来幹細胞の保存
  • その他の幹細胞保存の種類

第14章 米国における臍帯血市場のリーダー:比較分析

  • 臍帯血の登録
  • ViaCord
  • Cryo-Cell International
  • 米国における民間臍帯血バンクのトップ3の比較

第15章 世界における臍帯血市場のリーダー:比較分析

  • Cryo-Save Group (an Esperite N.V Company)
  • China Cord Blood Corporation (Owned by Sanpower Group)
  • LifeCell International
  • 国際的な臍帯血バンクの比較

第16章 SWOT分析

第17章 臍帯血市場の規制

第18章 各種動向:比率分析

  • 科学論文の比率分析
  • 助成金付与の分析
  • 特許分析
  • 臨床試験の比率分析
  • 臍帯血保存の市場普及率

第19章 臍帯血オンラインマーケティング分析

  • Google AdWords における検索用語「臍帯血」のオンライントラフィックを獲得するためのコスト
  • Google AdWords における検索用語「臍帯細胞」のオンライントラフィックを獲得するためのコスト

第20章 臍帯血産業の主なベンチマーク

  • 臍帯血バンクに対する医療部門による見解
  • 親の認識率
  • 世界の保存率 (年度別)
  • 移植データ
  • 品質保証比較

第21章 品質保証比較

第22章 市場規模の分析

  • 定義
  • 調査手法
  • 市場参入企業のタイプ
  • 市場規模推計
  • 市場区分
  • 市場規模:セグメント別

第23章 臍帯血産業のリーダーシップ

第24章 世界の臍帯血会議・イベント

第25章 世界の臍帯血産業に影響を及ぼす投資家・買収

第26章 地域分析

  • 中国
  • フランスおよびイタリア
  • 台湾
  • エクアドル
  • 南アフリカ
  • ブラジル

第27章 総論:サマリー

付録

目次

Report Overview

After a rapid growth period through the mid-2000s, the global cord blood banking industry reached saturation and stabilized through approximately 2012. Since that time, the market has been aggressively consolidating. This has created both serious threats and novel opportunities for the industry.

Serious threats to the industry include low rates of utilization for stored cord blood, expensive cord blood transplantation procedures, difficulty educating obstetricians about cellular therapies, and an increasing trend toward industry consolidation.

There are also emerging opportunities for the industry, such as accelerated regulatory pathways for cell therapies in leading healthcare markets worldwide, including the United States, Japan, Europe and South Korea.

Cord Blood Industry Trends

New themes are impacting the industry, including the pairing of stem cell storage services with genetic and genomic testing services, as well as reproductive health services. Cord blood banks are diversifying into new types of stem cell storage, including umbilical cord tissue storage, placental blood and tissue, amniotic fluid and tissue, and dental pulp.

Cord blood banks are also investigating means of becoming integrated therapeutic companies, with LifebankUSA becoming an asset of the augmented immunity and longevity company Celularity and Americord announcing in a press release that it “intends to launch its first therapeutic product offering sometime in 2018.”

With approximately 450 companies offering cord blood banking services worldwide, maturation of the market means that each company is fighting harder for market share.

Cord Blood Industry Consolidation

Growing numbers of investors are now entering the marketplace, with M&A activity accelerating in the U.S. and abroad. In the United States, AMAG Pharmaceuticals sold Cord Blood Registry (CBR) to GI partners for $530 million in June 2018. AMAG had previously bought CBR for $700 million in 2015. GI Partners, a private equity investment firm, simultaneously acquired CBR and California Cryobank (CCB) to merge the companies into a single entity that will be the global leader in stem cell storage and reproductive tissue services.

Holding companies are also emerging as a global theme, allowing for increased operational efficiency and economy of scale. Cryoholdco has established itself as the market leader within Latin America. Created in 2015, Cryoholdco is a holding company that will control nearly 200,000 stem cell units by the end of 2018. It now owns six cord blood banks, as well as a dental stem cell storage company.

Globally, networks of cord blood banks are also commonplace, with Sanpower Group establishing dominance in Asia. Although Sanpower has been quiet about its operations, its website states:

“In 2016, Sanpower Group and its subsidiary Nanjing Cenbest announced their participation in founding a foundation to buy CO. In the same year, Nanjing Cenbest also acquired Shandong Cord Blood Bank. As a result, Sanpower now holds 4 licenses out of only 7 issued provincial-level cord blood bank licenses in China. It has reserved over 900,000 cord blood samples at home, and the associated reserves amount to almost 1,200,000 when counting in the Cordlife reserves across Southeast Asian countries and regions.”

This positions Sanpower Group and its subsidiary Nanjing Cenbest as the world's largest cord blood banking operator not only in China and Southeast Asia, but in the world.

The number of cord blood banks in Europe has dropped by approximately one-third over the past ten years, from approximately 150 to 100. The industry leaders in this market segment include FamiCord Group, who has executed a dozen M&A transactions, and Vita34, who has executed approximately a half dozen. Stemlab, the largest cord blood bank in Portugal, also executed three acquisition deals prior to being acquired by FamiCord in July 2018.

FamiCord is now the leading stem cell bank in Europe, controlling over 263,000 cord blood and tissue units among its network of banks and over 347,000 biological samples of all types. This places it among the leading cord blood banks worldwide.

Dozens of other cord blood industry acquisitions have also occurred worldwide, with the highest frequency occurring within the United States, Europe, and Latin America.

Digital Competition for Cord Blood Banking Services

Digital competition for cord blood has been growing increasingly competitive. The term “cord blood” has now become one of the 20 most expensive search terms on Google. Winning online traffic through Google AdWords for the search phrase “Cord Blood” now costs $45.87 in the United States.

The cost for acquiring traffic through Google AdWords for the phrase “Cord Blood” is $32.91 when all geographies are allowed.

Cord Blood Expansion Technologies

Because cord blood utilization is largely limited to use in pediatric patients, growing investment is flowing into ex vivo cord blood expansion technologies.

Key strategies being explored for this purpose include:

  • Nicotinamide-mediated (NAM) expansion
  • Notch ligand
  • SR-1
  • UM171
  • PGE2
  • Enforced fucosylation

Currently, the following companies have ex vivo cord blood expansion products in Phase II clinical trials:

  • 1. Gamida Cell Ltd.
  • 2. Nohla Therapeutics
  • 3. Excellthera

Magenta Therapeutics has a Phase I trial underway for its cord blood expansion technology.

Growing numbers of investors are also entering the cord blood banking marketplace, led by groups such as GI Partners, ABS Capital Partners & HLM Management, KKR & Company, Bay City Capital, GTCR, LLC, Excalibur, and more.

Global Cord Blood Banking Industry Dynamics

In 2008, a Taiwanese company, HealthBanks Biotech Company Ltd. became the first company to offer cord tissue storage. It was not until July 2010 that the first private U.S. cord blood bank began offering the service (Cord Blood Registry). Since then, the trend of cord tissue storage has had a major impact on the cord blood banking industry, with many cord blood banks worldwide now offering the service.

In China, the government shocked the industry by announcing that only one cord blood bank would be allowed to operate within each province, and official government support, authorization, and permits would be required.

In Italy and France, it is illegal to privately store one's cord blood, which has fully eliminated the potential for a private market to exist within the region.

In Ecuador, the government is now creating the first public cord blood bank and has instituted laws such that private cord blood banks cannot approach women about private cord blood banking options during the first six months of pregnancy. This created a crisis for the private banks, and there are now only two remaining in Ecuador.

Most recently, India's Central Drugs Standard Control Organization (CDSCO) restricted commercial banking of stem cells from most biological materials, including cord tissue, placenta, and dental pulp stem cells, leaving only umbilical cord blood banking as “permitted and licensed” within the country.

While market factors can vary by geography, it is crucial to have a global understanding of the market. Research advances, clinical trial findings, and technology advances do not know international boundaries.

The cord blood market is global in nature and understanding dynamics limited to your region is not sufficient for making strategic, informed, and profitable decisions.

Cord Blood Report Highlights

This 265 page reports includes:

  • Market size determinations for cord blood and tissue storage, with projections to 2022
  • Volumes of cord blood and cord tissue storage worldwide
  • Rates of worldwide cord blood storage (units per year)
  • Rates of cord blood utilization
  • Trend rate data for umbilical cord blood grants, patents, and scientific publications
  • Clinical trial analysis, including comparison of cord blood vs. cord tissue trials
  • Current and future conditions treatable with cord blood
  • Regulatory pathways affecting cord blood banking in major healthcare markets
  • Digital marketing assessment and comparison of industry leaders
  • Competitive environment analysis, including identification of market leaders
  • Leading investors within the cord blood marketplace
  • Medical opinions of cord blood banking
  • Crucial trends and unmet market needs
  • And more

Companies Mentioned

  • ABS Capital Partners & HLM Management
  • AllCells
  • AMAG Pharmaceuticals
  • AlphaCord
  • Americord
  • Bay City Capital
  • BioEden
  • Biocell Center
  • Biosafe
  • CariCord
  • Cell Care (Australia)
  • Cesca Therapeutics
  • China Cord Blood Corporation (CCBC)
  • CorCell
  • Cord Blood Registry (CBR)
  • Cordlife
  • Core23 BioBank
  • Crioestaminal
  • Cryo-Cell International
  • Cryoholdco
  • Cryolife
  • CryoSave
  • Dentcell
  • Excalibur
  • FamilyCord
  • Fate Therapeutics
  • Future Health Biobank
  • Gamida Cell Ltd.
  • GeneCell International
  • Genesis Bank
  • GI Parnters
  • GTCR, LLC
  • HealthBaby
  • HealthBanks Biotech Company Ltd.
  • Human Longevity Inc.
  • Insception Lifebank
  • KKR & Company
  • LifebankUSA
  • LifeCell International
  • Lonza
  • MAZE
  • MiracleCord
  • Nanjing Cenbest
  • Natera, Inc. (EverCordTM)
  • New England Cord Blood Bank
  • National Cord Blood Program (NCBP) at the New York Blood Center
  • Nohla Therapeutics
  • Novartis
  • PacifiCord
  • PerkinElmer
  • Pluristem Therapeutics
  • Precious Cells Group (now in administration, along with Pharmacells Ltd.)
  • PromoCells
  • ReeLabs
  • Sanpower Group
  • Shandong Cord Blood Bank
  • Stem Cell Cryobank
  • STEMCELL Technologies
  • StemCyte
  • Thermo Fisher Scientific
  • Transcell Biologics Pvt Ltd,
  • VAULT SC Inc.
  • ViaCord
  • Vita34 AG
  • And More

Table of Contents

I. Abstract

  • A. Global Market Requires Global Understanding
  • B. Cord Blood Stem Cells, Compared to Other Stem Cell Alternatives
  • C. Awareness Levels as a Factor Impacting Market Penetration
  • D. Digital Competition for Cord Blood
  • E. Key Report Findings

II. Timeline of Key Events

III. Technical & Medical Characteristics of Cord Blood

  • A. Introduction to Cord Blood and Cord Tissue
  • B. Definitions and Nomenclature
  • C. Technical Advantages of Cord Blood
  • D. Likelihood of Needing a Stem Cell Transplant
  • E. Comparison of Cord Blood, Bone Marrow, & Peripheral Blood Stem Cell Transplant
  • F. Conditions Treatable with Cord Blood Transplant

IV. Cord Blood Market Overview

  • A. Stem Cell Storage Service Offerings
  • B. Public vs. Private Cord Blood Storage

V. Cord Tissue Market Overview

  • A. History of Cord Tissue Storage
  • B. Comparison of Cord Blood & Cord Tissue Storage
  • C. Clinical Trials Investigating Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
  • D. Sources of Mesenchymal Stem Cells
  • E. Market Penetration of Cord Tissue Storage within the U.S.
  • F. Market Penetration of Cord Tissue Storage Worldwide
  • G. Pricing of Cord Tissue Storage (Global Analysis)

VI. Benefits of Mesenchymal Stem Cells

  • A. Key Dates in the Discovery of MSCs
  • B. Physical Assessment of MSCs
  • C. Benefits of MSCs Relative to Other Stem Cells
    • 1. Well-Characterized
    • 2. Non-Controversial
    • 3. Diverse Differentiation Potential
    • 4. Ease of Growth in Culture
    • 5. Flexible Propagation
    • 6. Clinically Relevant Volumes
    • 7. Role as Regulatory Cells
    • 8. Delivery of Gene Products
    • 9. Favorable Immune Status
    • 10. Commercially Available Research Tools

VII. Cord Blood Industry Accreditations

  • A. Overview of Cord Blood Industry Accreditation
  • B. AABB Accreditation

VIII. Key Processing Technologies within the Cord Blood Marketplace

  • A. AutoXpress® Platform (“AXP®”) and BioArchive System (By Thermogenesis, a Division of Cesca Therapeutics in Rancho Cordova, California, USA)
  • B. Sepax (By Biosafe, in Eysins, Switzerland)
  • C. PrepaCyte®-CB (By BioE in St. Paul, Minnesota, USA) - Cryo-Cell Purchased Rights to it in 2015
  • D. Cord Blood 2.0TM (By Americord, in New York, NY, USA)
  • E. Other Cord Blood Processing Technologies

IX. Strategic Collaborations: Key Alliances within the Cord Blood Industry

  • A. Cord Blood Registry and Women's Health Alliance (Largest Women's Healthcare Groups)
  • B. ViaCord and Destination Maternity (Largest Retailer of Maternity Clothing)
  • C. Precious Cells Miracle and the Croydon Health Services NHS Trust
  • D. CarePilot and “Cord for Life” (Lifeforce Cryobank's Cord Blood Storage Program)
  • E. Cesca Therapeutics and UpState Public Cord Blood Bank
  • F. New York Blood Center and Pluristem Therapeutics Collaborate on Adjuvant Therapy for Cord Blood Transplantation

X. Pairing Cord Blood Banking with Prenatal / Neonatal / Maternal Health Services

  • A. Natera, a leader in genetic testing, launches EverCord™ Cord Blood and Tissue Banking Services (March 2017)
  • B. ViaCord, owned by parent company PerkinElmer, launched Newborn Genetic Screening (August 2017)
  • C. Human Longevity Inc. acquired LifeBankUSA (owned by Celgene); LifeBankUSA Now Passed to Celularity, Inc.
  • D. AMAG Pharmaceuticals acquired Cord Blood Registry to bolster its portfolio of maternal health products (June 2015)
  • E. Donor Egg Bank offers free processing of its clients' newborn cord blood through its sister company, FamilyCord

XI. Cord Blood Industry Consolidation (Mergers and Acquisitions)

  • A. Global Analysis of Mergers & Acquisitions
  • B. Role of Holding Companies within the Global Cord Blood Industry

XII. Technologies for Cord Blood Stem Cell Expansion

  • A. Key Strategies for Cord Blood Expansion
    • 1. NiCord
    • 2. Notch-1 Ligand
    • 3. StemRegenin-1 (SR1)
    • 4. UM171
    • 5. Enforced Fucosylation
  • B. Case Study: Gamida Cell as an Industry Leader in Cord Blood Expansion Technology

XIII. Diversification of Stem Cell Storage Services

  • A. Dental Stem Cell Storage
    • 1. Overview of Dental Stem Cell Storage
    • 2. Leading Dental Stem Cell Companies
    • 3. Timeline of Events for Dental Stem Cell Companies
    • 4. Key Competitors for Dental Stem Cell Storage
    • 5. BioEden, Leading Provider of Dental Stem Cell Storage Worldwide
  • B. Adipose-Derived Stem Cell Storage
  • C. Other Types of Stem Cell Storage

XIV. Comparison of U.S. Cord Blood Market Leaders

  • A. Cord Blood Registry
  • B. ViaCord
  • C. Cryo-Cell International
  • D. Comparison of Top 3 Private U.S. Cord Blood Banks

XV. Comparison of Global Cord Blood Market Leaders

  • A. Cryo-Save Group (an Esperite N.V Company)
  • B. China Cord Blood Corporation (Owned by Sanpower Group)
  • C. LifeCell International
  • D. Comparison of International Cord Blood Banks

XVI. SWOT Analysis for Cord Blood Industry

  • A. Strengths
  • B. Weaknesses
  • C. Opportunities
  • D. Threats

XVII. Regulation of the Cord Blood Marketplace

  • A. Regulation of HCT/Ps by the U.S. FDA
  • B. 21st Century Cures Act and REGROW Act
  • C. Accelerated Approval Pathways for Cell Therapies in Japan
  • D. Accelerated Approval Regulator Pathways Worldwide

XVIII. Trend Rate Analysis

  • A. Scientific Publication Rate Analysis
  • B. Grant Funding Analysis
  • C. Patent Analysis
  • D. Clinical Trial Analysis
  • E. Market Penetration Rate of Cord Blood Storage

XIX. Cord Blood Online Marketing Analysis

  • A. Cost to Win Online Traffic for the Term “Cord Blood” in Google AdWords
  • B. Cost to Win Online Traffic for the Term “Cord Tissue” in Google AdWords

XX. Key Cord Blood Industry Benchmarks

  • A. Medical Society Opinions of Cord Blood Banking
  • B. Rates of Parental Awareness
  • C. Rates of Worldwide Storage, by Year
  • D. Transplant Data
  • E. Impact of Haploidentical Transplant

XXI. Quality Guarantee Comparison

XXII. Market Size Analysis

  • A. Definitions
  • B. Methodology
    • 1. Roll-up all competitor sales (“Gold Standard”)
    • 2. Use a weighted analysis of industry leaders (“Silver Standard”)
    • 3. Survey customers for how much they spend in the market (“Bronze Standard”)
  • C. Types of Market Participants
    • 1. Largest Market Participants
    • 2. Mid-Sized Market Participants
    • 3. Small Sized Participants
    • 4. Public Cord Blood Banking Sector
    • 5. Summary of Findings
  • D. Market Size Determination for Cord Blood and Tissue Banking Market
  • E. Market Segmentation for All Applications of Cord Blood and Cord Tissue
    • 1. Biobanking
    • 2. Use in Hematopoietic Stem Cell Transplantation (HSCT)
    • 3. Cellular Therapies
    • 4. Genetic Manipulation
    • 5. Research Tools
  • F. Market Size Determinations by Market Segment

XXIII. Cord Blood Industry Leadership

  • 1. Dr. Elaine Gluckman
  • B. Top Ten Most Influential Cord Blood Banks Worldwide

XXIV. Global Cord Blood Conferences and Events

XXV. Investors and Acquisitions Impacting the Global Cord Blood Industry

  • A. Investors Impacting the Global Cord Blood Market
  • B. Three Strange Similarities between Acquisition of Cord Blood Registry & ViaCord

XXV. Geographic Analysis of Evolving Cord Blood Industry Conditions

  • A. China
  • B. France and Italy
  • C. Taiwan
  • D. Ecuador
  • E. South Africa
  • F. Brazil

XXVI. Summary of Conclusions

APPENDIX A -Conditions Treatable with Hematopoietic Stem Cell Transplant (Including Cord Blood Stem Cell Transplant)

APPENDIX B - AABB Accredited Cord Blood Banks Worldwide

APPENDIX C - List of U.S. Cord Blood Banks by Type of Bank (Private, Hybrid, or Public)

APPENDIX D - Global List of Cord Blood Banks Worldwide

LIST OF TABLES AND FIGURES

  • FIGURE 1. Cord Blood Market Segmentation
  • FIGURE 2. Sources of Mesenchymal Stem Cells (MSCs)
  • FIGURE 3. Benefits of MSCs Relative to Other Stem Cells
  • FIGURE 4. Visualization of "Cord Blood" Clinical Trials (RePORTER Tool)
  • FIGURE 5. Leading Landing Page Used by CBR
  • FIGURE 6. Common Cryo-Cell Landing Page
  • FIGURE 7. Common ViaCord Landing Pages
  • FIGURE 8. Comparison of Umbilical Cord Blood vs. Umbilical Cord Tissue
  • FIGURE 9. Cord blood treatment options
  • FIGURE 10. Cost to Win Online Traffic for Term "Cord Blood" in Google AdWords on a Global Basis
  • FIGURE 11. Cost to Win Online Traffic for Term "Cord Blood" in Google AdWords within the U.S.
  • FIGURE 12. Density of Research Grants in the U.S. Containing "Cord Blood" in Description
  • FIGURE 13. Key Processing Technologies within the Cord Blood Banking Marketplace
  • FIGURE 14. Gamida Cell's Clinical Pipeline Involving Its Cord Blood Derived Products
  • FIGURE 15. Geographical Breakdown of "Cord Blood" Clinical Trials Registered at ClinicalTrials.gov
  • FIGURE 16. Ground-breaking Years in Transplant History
  • FIGURE 17. Key Dates in the Discovery of Mesenchymal Stem Cells
  • FIGURE 18. Map of Current Mesenchymal Stem Cell (MSC) Clinical Trials on ClinicalTrials.gov
  • FIGURE 19. Search Terms Containing the Phrase "Cord Blood" Within Them (Geography: USA Only)
  • FIGURE 20. Search Terms Containing the Phrase "Cord Blood" Within Them (Geography: Worldwide)
  • FIGURE 21. Sites of Organizations that Have Received Cord Blood Grants
  • FIGURE 22. Technical Advantages of Cord Blood over Bone Marrow or Peripheral Blood
  • FIGURE 23. Leading Assignees for Cord Blood Patents
  • FIGURE 24. Potential Strategies for Cord Blood Expansion
  • GRAPH 1. Likelihood of Requiring a Stem Cell Transplant (From Cord Blood, Bone Marrow, or Peripheral Blood)
  • GRAPH 2. # of "Cord Blood" Patents by Country (Title and Abstract Search)
  • GRAPH 3. # of Grants Funding Projects with "Cord Blood" in Description (RePORTER Tool)
  • GRAPH 4. Breakdown of Global Cord Blood and Tissue Market by Type of Participant
  • GRAPH 5. Countries with AABB Accredited Cord Blood Facilities
  • GRAPH 6. Market Contributions by Type of Market Participants
  • GRAPH 7. Market Contributions by Type of Market Segment
  • GRAPH 8. Number of Clinical Trials with "Cord Blood" in the Description
  • GRAPH 9. Number of Cord Blood Units in the BMDW Cord Blood Registry, by Year
  • GRAPH 10. Percentage of Cord Blood Banks Worldwide Offering Cord Tissue Storage Services
  • GRAPH 11. Percentage of Global Market for Cord Blood and Cord Tissue Banking
  • GRAPH 12. Registry Transplants by Cell Source
  • GRAPH 13. Types of Transplants Used by the 70,000 Patients Requiring Hematopoietic Stem Cell Transplantation Each Year
  • GRAPH 14. Year-Over-Year Comparison of Stem Cell Scientific Publications, by Stem Cell Type
  • TABLE 1. U.S. Cord Blood Banks Offering Cord Tissue Storage in 2013 (Historical Snapshot 1)
  • TABLE 2. U.S. Cord Blood Banks Offering Cord Tissue Storage in 2015 (Historical Snapshot 2)
  • TABLE 3. Adulthood Probability of Requiring a Stem Cell Transplant
  • TABLE 4. Breakdown of Global Market by Type of Participant
  • TABLE 5. Childhood Probability of Requiring a Stem Cell Transplant
  • TABLE 6. Clinical Trials Investigating the Use of Cord Tissue Derived Mesenchymal Stem Cells (CT-MSCs)
  • TABLE 7. Clinical Trials Underway Involving Use of Wharton's Jelly, a Rich Source of Cord Tissue MSCs
  • TABLE 8. Companies Offering Adipose-Derived Stem Cell Storage (Both Cord Blood Banks and Specialty Companies)
  • TABLE 9. Companies Offering Dental Stem Cell Storage, Including Cord Blood Banks and Specialty Companies
  • TABLE 20. Comparative Analysis of Pricing Among Leading U.S. Private Cord Blood Banks
  • TABLE 21. Comparison of Acquisition of Cord Blood Registry by AMAG Pharmaceuticals and ViaCord by PerkinElmer
  • TABLE 22. Comparison of Quality Guarantees Among Private U.S. Cord Blood Banks (Ranked by Value of the Guarantee)
  • TABLE 23. Comparison of Services and Features Among Leading Private Cord Blood Banks Worldwide
  • TABLE 24. Comparison of Services and Features Among Leading U.S. Private Cord Blood Banks
  • TABLE 25. Comparison of Stem Cell Publication Rates by Stem Cell Type
  • TABLE 26. Cord Blood Banking Opinions Issued by Medical Societies
  • TABLE 27. Cord Blood Clinical Trials Registered at ClinicalTrials.gov
  • TABLE 28. Cord Blood Units in the Bone Marrow Donors Worldwide Database
  • TABLE 29. Countries Containing AABB Accredited Cord Blood Banks
  • TABLE 30. Disease Categories That May Be Treatable with HSCT in the Future
  • TABLE 31. Disease Categories Treatable with Hematopoietic Stem Cell Transplantation (HSCT)
  • TABLE 32. Esperite N.V. Subsidiaries Operating Worldwide
  • TABLE 33. Free Cord Blood Programs for Families in Need in the U.S.
  • TABLE 34. Geographic Breakdown of "Cord Blood" Clinical Trials Registered at ClinicalTrials.gov
  • TABLE 35. Global Cord Blood Conference and Events
  • TABLE 36. Global Private Cord Blood and Tissue Banking Market, by Type of Market Participant
  • TABLE 37. Google AdWords Pay-Per-Click Prices for Cord Blood Related Search Terms
  • TABLE 38. Industry Investors within the Cord Blood Market
  • TABLE 39. Major Acquisitions within the Global Cord Blood Market
  • TABLE 40. Market Contribution in USD ($) by Market Segment
  • TABLE 41. Market Contribution in USD ($) by Type of Market Participant
  • TABLE 42. Market Size Determinations by Market Segment
  • TABLE 43. Number of Cord Blood and Tissue Units Stored by Mid-Sized Private Cord Blood Banks
  • TABLE 44. Number of Cord Blood and Tissue Units Stored in Largest Private Cord Blood Banks
  • TABLE 45. Opportunities within the Global Cord Blood Banking Market
  • TABLE 46. Patents Containing "Cord Blood" in the Title or Abstract (Google Patent Search)
  • TABLE 47. Percent of Cord Blood Banks Worldwide Offering Cord Tissue Storage Services
  • TABLE 48. Percent of Total Global Market by Type of Cord Blood Bank
  • TABLE 49. Pricing Structures for Umbilical Cord Tissue
  • TABLE 50. Strengths of the Global Cord Blood Banking Market
  • TABLE 51. Threats to the Global Cord Blood Banking Market
  • TABLE 52. Timeline of Key Events within the Cord Blood Industry
  • TABLE 53. Transplants by Cell Source
  • TABLE 54. Trend Rate Analysis of Cord Blood and Cord Tissue Scientific Publications
  • TABLE 55. Trend Rate Analysis of Cord Blood Grants (RePORTER Tool)
  • TABLE 56. Trends in Cord Blood Industry Growth by Geography and Sector
  • TABLE 57. Types of Stem Cell Banking
  • TABLE 58. Unique Differentiators for CBR, ViaCord, and Cryo-Cell
  • TABLE 59. Weaknesses of the Global Cord Blood Banking Market
  • TABLE 60: Fetal Sources for Mesenchymal Stem Cell (MSC) Isolation
  • TABLE 61: Adult Sources for Mesenchymal Stem Cell (MSC) Isolation
  • TABLE 62: Cord Blood Banks Securing Cord Blood Patents as the Assignee
Back to Top